Table 3 Effect of surfactant on the risk of ECMO/death for lung diseases associated with HRF among the entire study cohort consisting of both early inhaled nitric oxide and control groups

From: Impact of early surfactant and inhaled nitric oxide therapies on outcomes in term/late preterm neonates with moderate hypoxic respiratory failure

Diagnosis

ECMO/death for surfactant-treated group, n (%)

ECMO/death for the no surfactant group, n (%)

P-value

Primary pulmonary hypertension

12/42 (28.6)

7/37 (19)

0.43

RDS

1/45 (2.2)

2/7 (28.6)

0.04

Perinatal aspiration syndrome

11/79 (14)

14/47 (30)

0.04

Pneumonia/sepsis

1/25 (4)

5/16 (31)

0.03

Lung diseases other than primary pulmonary hypertension

14/150 (9.3)

21/70 (30)

<0.001

  1. Abbreviations: ECMO, extracorporeal membrane oxygenation; HRF, hypoxic respiratory failure; RDS, respiratory distress syndrome.
  2. Data are shown for babies who met ECMO/death outcome for each diagnosis, for surfactant-treated and untreated groups as number (n) and percent (%).
Back to article page